A Phase 3 interventional study of Stapokibart and Placebo in Prurigo Nodularis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Keymed Biosciences Co.Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of Stapokibart Injection in the treatment of subjects with prurigo nodularis, and observe pharmacokinetic characteristics, pharmacological effects, and immunogenicity.
Chronic prurigo (CPG) is an independent chronic inflammatory skin disease characterized by chronic itching and multiple local or systemic prurigo lesions. Prurigo nodularis (PN) is the main subtype of CPG.
38 studies on the registry are indexed under Prurigo; 10 are open to participants now.
This study's enrollment of 200 is above the median of 135 across 31 interventional studies indexed under Prurigo.
Browse Prurigo studies →Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stapokibart Injection, subcutaneous injection (SC)
Biological: Stapokibart
subcutaneous injection (SC)
Other: Placebo
Stapokibart Injection
Placebo
Proportion of subjects with ≥4-point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at week 24
The Worst Itch Numerical Rating Scale (WI-NR) is a patient-reported outcome (PRO) consisting of individual items with scores ranging from 0 ("no itching") to 10 ("the most severe itching imaginable"). Subjects are required to use this scale to rate the severity of their most severe itching in the past 24 hours.
Time frame: Up to week 24
Proportion of subjects with Investigator's Global Assessment score of 0 or 1 for PN stage (IGA-CNPG S) at week 24
IGA-CNPG-S stands for Investigator Global Assessment of Chronic Nodular Prurigo - Severity scale, a clinical tool used to rate the overall severity of chronic nodular prurigo (CNPG) by evaluating lesion number, size, and inflammation.
Time frame: Up to week 24
Change from the baseline in the WI-NRS at each other visit
Time frame: Up to week 24
Proportion of subjects with Investigator's Global Assessment score of 0 or 1 for PN Activity (IGA-CNPG A) at each visit
A clinician-assessed scale to evaluate the overall appearance of lesions in chronic nodular prurigo
Time frame: Up to week 24
Change from baseline in Dermatology Life Quality Index (DLQI) score at each visit
A patient-reported questionnaire measuring the impact of skin disorders on daily life and quality of life.
Time frame: Up to week 24
Change from baseline in Skin Pain NRS at each visit
A numerical rating scale for patients to self-assess the intensity of skin pain.
Time frame: Up to week 24
Change from baseline in Sleep NRS at each visit
A numeric scale used to quantify sleep disturbance caused by disease symptoms.
Time frame: Up to week 24
Change from baseline in Hospital Anxiety and Depression Scale (HADS) at each visit
A validated scale for screening anxiety and depression symptoms in clinical populations.
Time frame: Up to week 24
Change from baseline in the European Health Questionnaire 5 Dimensions (EQ-5D-5L) at each visit
A standard five-dimension tool to evaluate general health status and health-related quality of life.
Time frame: Up to week 24
Safety parameters
Incidence of treatment-emergent adverse events (TEAEs).
Time frame: Up to week 32
Pharmacokinetics (PK)
Concentration of CM310 in serum
Time frame: Up to week 32
Pharmacodynamics (PD)
Change from baseline in serum thymus activation-regulated chemokine (TARC) concentration.
Time frame: Up to week 32
Anti-drug antibodies (ADA)
Incidence of ADA.
Time frame: Up to week 32
Pharmacodynamics (PD)
Change from baseline in serum total immunoglobulin E (IgE) concentration.
Time frame: Up to week 32
Ran from Jun 2024 to primary completion in Feb 2026, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart